Drugs / AT193
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05072886 | Apr 2022 → Aug 2023 | psoriasis | Azora Therapeutics Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT04989517 | Nov 2021 → Mar 2023 | hidradenitis suppurativa | Azora Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AT193 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04989517 ↗ |
| Route | Topical | “Topical applied daily” NCT04989517 ↗ |